Spinal Sarcopenia Cohort Study (SarcoSpine)

Sarcopenia Clinical Trial

— SarcoSpine  

Official title:

Sarcopenia of Spine: a Prospective Cohort Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03962530
• Other study ID #: 20-2019-19
• Status: Not yet recruiting
• Start date: August 2019
• Est. completion date: July 2023

Study information

• Verified date: June 2019
• Source: Seoul National University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sarcopenia on lumbar paraspinal muscles is receiving renewed attention as a cause of spinal degeneration. However, there are few studies on the precise concept and diagnostic criteria for spinal sarcopenia. Here, we develop the concept of spinal sarcopenia in community-dwelling healthy elderly people. In addition, we aim to observe the natural aging course of paraspinal muscle and back muscle strength, and investigate the association between conventional sarcopenic indices and spinal sarcopenia.

This is a prospective observational cohort study with 120 healthy community-dwelling elderly people for 4 years. All subjects will be recruited according to no sarcopenia, possible sarcopenia, sarcopenia, and severe sarcopenia groups. The primary outcomes of this study are isokinetic back muscle strength and lumbar paraspinal muscle quantity and quality using lumbar spine MRI. Conventional sarcopenic indices and spine specific outcomes such as spinal sagittal balance, back performance scale, and Sorenson test will be also assessed. The data will be analysed using the intention-to-treat principle.

Description:

This is a prospective observational cohort study with 120 healthy community-dwelling elderly people in a single center (SMG-SNU Boramae Medical Center). Individual follow-up will last 4 years. Elderly people (≥ 65 years old) who are community-dwellers and able to walk with or without assistive devices) will be included. Sarcopenia can be divided by two stages: 1) possible sarcopenia (PS) defined by low handgrip strength and/or low gait speed and 2) sarcopenia (SA) confirmed by low handgrip strength and/or low gait speed and low muscle mass by the consensus report of the Asian working group for sarcopenia. No sarcopenia (NS) group is added to this classification, and the study participants are classified into three groups (NS, PS, and SA) after the screening tests. All outcome variables will be collected at baseline, 2 and 4 years. However, L-S spine MRI for lumbar paraspinal muscle quantity and quality will be performed only at baseline.

Data will be collected using a standardised data entry form and entered into the data management system. The intention-to-treat principle will be used for data analysis. Participant characteristics will be described using means and standard deviations for continuous data and frequencies and percentages for categorical data. The three groups will be compared using an analysis of variance (ANOVA) or the non-parametric equivalence Kruskal-Wallis test if required. To compare paired data (intra-group) between two different points, we will use repeated-measures ANOVA and Friedman tests for continuous and non-parametric data, respectively.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: July 2023
• Est. primary completion date: July 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

1. Elderly people aged 65 and over;

2. Community dweller;

3. Ambulator with or without an assistive device.

Exclusion Criteria:

1. low back pain with moderate severity (numeric rating scale 5 and over);

2. history of any types of lumbar spine surgery;

3. history of hip fracture surgery and arthroplasty of hip or knee;

4. contraindications for MRI (such as cardiac pacemaker, implanted metallic objects, and claustrophobia);

5. disorders in central nervous system (such as stroke, parkinsonism, spinal cord injury);

6. cognitive dysfunction (Mini Mental State Examination score < 24);

7. communication disorder (such as severe hearing loss);

8. severe cardiopulmonary disease (such as heart failure with New York Heart Association Class III or IV);

9. uncontrolled chronic disease (such as hypertension with systolic blood pressure >165 and diastolic blood pressure >95);

10. musculoskeletal condition affecting physical function (such as amputation of limb);

11. long term use of corticosteroids due to inflammatory disease;

12. malignancy requiring treatment within 5 years; and

13. other medical conditions which needs active treatment; patients who refuse to participate in a study will also be excluded.

Related Conditions & MeSH terms

• Sarcopenia
• Spinal Disease
• Spinal Diseases

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Seoul National University Hospital	National Research Foundation of Korea

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of isokinetic back muscle strength	Isokinetic back extensor strength using Biodex	Baseline, 24 months, and 48 months
Primary	Lumbar paraspinal muscle quantity and quality	Lumbar paraspinal muscle examination using L-S spine MRI	Baseline
Secondary	Change of appendicular limb mass	Appendicular limb mass measure using wholebody DEXA and BIA	Baseline, 24 months, and 48 months
Secondary	Change of short physical performance battery	Physical performance measure by walking speed, balance test, and chair standing	Baseline, 24 months, and 48 months
Secondary	Laboratory test with biomarker	Serum IL-6 level	Baseline, 24 months, and 48 months
Secondary	Change of spinal sagittal balance	Spinopelvic parameters using simple whole spine X-ray	Baseline, 24 months, and 48 months
Secondary	Change of back performance scale	Sock Test, the Pick-up Test, the Roll-up Test, the Fingertip-to-Floor Test, and the Lift Test.	Baseline, 24 months, and 48 months